Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Identifieur interne : 000665 ( PubMed/Corpus ); précédent : 000664; suivant : 000666Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Auteurs : Chean Yeah Yong ; Swee Keong Yeap ; Kok Lian Ho ; Abdul Rahman Omar ; Wen Siang TanSource :
- International journal of nanomedicine [ 1178-2013 ] ; 2015.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Base Sequence, Blotting, Western, Capsid Proteins (chemistry), Capsid Proteins (metabolism), Enzyme-Linked Immunosorbent Assay, Female, Immunophenotyping, Influenza A virus (chemistry), Influenza A virus (metabolism), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Mice, Mice, Inbred BALB C, Microscopy, Electron, Transmission, Molecular Sequence Data, Nanoparticles (chemistry), Nanoparticles (metabolism), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Vaccination, Vaccines, Synthetic (immunology), Vaccines, Synthetic (therapeutic use), Viral Matrix Proteins (chemistry), Viral Matrix Proteins (metabolism).
- MESH :
- chemical , chemistry : Capsid Proteins, Viral Matrix Proteins.
- chemical , genetics : Recombinant Fusion Proteins.
- chemical , immunology : Influenza Vaccines, Recombinant Fusion Proteins, Vaccines, Synthetic.
- chemical , metabolism : Capsid Proteins, Viral Matrix Proteins.
- chemistry : Influenza A virus, Nanoparticles.
- immunology : Orthomyxoviridae Infections.
- metabolism : Influenza A virus, Nanoparticles.
- prevention & control : Orthomyxoviridae Infections.
- chemical , therapeutic use : Influenza Vaccines, Vaccines, Synthetic.
- virology : Orthomyxoviridae Infections.
- Amino Acid Sequence, Animals, Base Sequence, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Female, Immunophenotyping, Mice, Mice, Inbred BALB C, Microscopy, Electron, Transmission, Molecular Sequence Data, Vaccination.
Abstract
Influenza A virus poses a major threat to human health, causing outbreaks from time to time. Currently available vaccines employ inactivated viruses of different strains to provide protection against influenza virus infection. However, high mutation rates of influenza virus hemagglutinin (H) and neuraminidase (N) glycoproteins give rise to vaccine escape mutants. Thus, an effective vaccine providing protection against all strains of influenza virus would be a valuable asset. The ectodomain of matrix 2 protein (M2e) was found to be highly conserved despite mutations of the H and N glycoproteins. Hence, one to five copies of M2e were fused to the carboxyl-terminal end of the recombinant nodavirus capsid protein derived from Macrobrachium rosenbergii. The chimeric proteins harboring up to five copies of M2e formed nanosized virus-like particles approximately 30 nm in diameter, which could be purified easily by immobilized metal affinity chromatography. BALB/c mice immunized subcutaneously with these chimeric proteins developed antibodies specifically against M2e, and the titer was proportional to the copy numbers of M2e displayed on the nodavirus capsid nanoparticles. The fusion proteins also induced a type 1 T helper immune response. Collectively, M2e displayed on the nodavirus capsid nanoparticles could provide an alternative solution to a possible influenza pandemic in the future.
DOI: 10.2147/IJN.S77405
PubMed: 25897220
Links to Exploration step
pubmed:25897220Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.</title>
<author><name sortKey="Yong, Chean Yeah" sort="Yong, Chean Yeah" uniqKey="Yong C" first="Chean Yeah" last="Yong">Chean Yeah Yong</name>
<affiliation><nlm:affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yeap, Swee Keong" sort="Yeap, Swee Keong" uniqKey="Yeap S" first="Swee Keong" last="Yeap">Swee Keong Yeap</name>
<affiliation><nlm:affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ho, Kok Lian" sort="Ho, Kok Lian" uniqKey="Ho K" first="Kok Lian" last="Ho">Kok Lian Ho</name>
<affiliation><nlm:affiliation>Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Omar, Abdul Rahman" sort="Omar, Abdul Rahman" uniqKey="Omar A" first="Abdul Rahman" last="Omar">Abdul Rahman Omar</name>
<affiliation><nlm:affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tan, Wen Siang" sort="Tan, Wen Siang" uniqKey="Tan W" first="Wen Siang" last="Tan">Wen Siang Tan</name>
<affiliation><nlm:affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25897220</idno>
<idno type="pmid">25897220</idno>
<idno type="doi">10.2147/IJN.S77405</idno>
<idno type="wicri:Area/PubMed/Corpus">000665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000665</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.</title>
<author><name sortKey="Yong, Chean Yeah" sort="Yong, Chean Yeah" uniqKey="Yong C" first="Chean Yeah" last="Yong">Chean Yeah Yong</name>
<affiliation><nlm:affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yeap, Swee Keong" sort="Yeap, Swee Keong" uniqKey="Yeap S" first="Swee Keong" last="Yeap">Swee Keong Yeap</name>
<affiliation><nlm:affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ho, Kok Lian" sort="Ho, Kok Lian" uniqKey="Ho K" first="Kok Lian" last="Ho">Kok Lian Ho</name>
<affiliation><nlm:affiliation>Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Omar, Abdul Rahman" sort="Omar, Abdul Rahman" uniqKey="Omar A" first="Abdul Rahman" last="Omar">Abdul Rahman Omar</name>
<affiliation><nlm:affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tan, Wen Siang" sort="Tan, Wen Siang" uniqKey="Tan W" first="Wen Siang" last="Tan">Wen Siang Tan</name>
<affiliation><nlm:affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of nanomedicine</title>
<idno type="eISSN">1178-2013</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Base Sequence</term>
<term>Blotting, Western</term>
<term>Capsid Proteins (chemistry)</term>
<term>Capsid Proteins (metabolism)</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Female</term>
<term>Immunophenotyping</term>
<term>Influenza A virus (chemistry)</term>
<term>Influenza A virus (metabolism)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Microscopy, Electron, Transmission</term>
<term>Molecular Sequence Data</term>
<term>Nanoparticles (chemistry)</term>
<term>Nanoparticles (metabolism)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Recombinant Fusion Proteins (genetics)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Vaccination</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Vaccines, Synthetic (therapeutic use)</term>
<term>Viral Matrix Proteins (chemistry)</term>
<term>Viral Matrix Proteins (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Capsid Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Capsid Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Influenza A virus</term>
<term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Influenza A virus</term>
<term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Base Sequence</term>
<term>Blotting, Western</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Female</term>
<term>Immunophenotyping</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Microscopy, Electron, Transmission</term>
<term>Molecular Sequence Data</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza A virus poses a major threat to human health, causing outbreaks from time to time. Currently available vaccines employ inactivated viruses of different strains to provide protection against influenza virus infection. However, high mutation rates of influenza virus hemagglutinin (H) and neuraminidase (N) glycoproteins give rise to vaccine escape mutants. Thus, an effective vaccine providing protection against all strains of influenza virus would be a valuable asset. The ectodomain of matrix 2 protein (M2e) was found to be highly conserved despite mutations of the H and N glycoproteins. Hence, one to five copies of M2e were fused to the carboxyl-terminal end of the recombinant nodavirus capsid protein derived from Macrobrachium rosenbergii. The chimeric proteins harboring up to five copies of M2e formed nanosized virus-like particles approximately 30 nm in diameter, which could be purified easily by immobilized metal affinity chromatography. BALB/c mice immunized subcutaneously with these chimeric proteins developed antibodies specifically against M2e, and the titer was proportional to the copy numbers of M2e displayed on the nodavirus capsid nanoparticles. The fusion proteins also induced a type 1 T helper immune response. Collectively, M2e displayed on the nodavirus capsid nanoparticles could provide an alternative solution to a possible influenza pandemic in the future. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25897220</PMID>
<DateCompleted><Year>2016</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>International journal of nanomedicine</Title>
<ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
</Journal>
<ArticleTitle>Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.</ArticleTitle>
<Pagination><MedlinePgn>2751-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S77405</ELocationID>
<Abstract><AbstractText>Influenza A virus poses a major threat to human health, causing outbreaks from time to time. Currently available vaccines employ inactivated viruses of different strains to provide protection against influenza virus infection. However, high mutation rates of influenza virus hemagglutinin (H) and neuraminidase (N) glycoproteins give rise to vaccine escape mutants. Thus, an effective vaccine providing protection against all strains of influenza virus would be a valuable asset. The ectodomain of matrix 2 protein (M2e) was found to be highly conserved despite mutations of the H and N glycoproteins. Hence, one to five copies of M2e were fused to the carboxyl-terminal end of the recombinant nodavirus capsid protein derived from Macrobrachium rosenbergii. The chimeric proteins harboring up to five copies of M2e formed nanosized virus-like particles approximately 30 nm in diameter, which could be purified easily by immobilized metal affinity chromatography. BALB/c mice immunized subcutaneously with these chimeric proteins developed antibodies specifically against M2e, and the titer was proportional to the copy numbers of M2e displayed on the nodavirus capsid nanoparticles. The fusion proteins also induced a type 1 T helper immune response. Collectively, M2e displayed on the nodavirus capsid nanoparticles could provide an alternative solution to a possible influenza pandemic in the future. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yong</LastName>
<ForeName>Chean Yeah</ForeName>
<Initials>CY</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yeap</LastName>
<ForeName>Swee Keong</ForeName>
<Initials>SK</Initials>
<AffiliationInfo><Affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ho</LastName>
<ForeName>Kok Lian</ForeName>
<Initials>KL</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Omar</LastName>
<ForeName>Abdul Rahman</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Wen Siang</ForeName>
<Initials>WS</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia ; Institute of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>04</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Int J Nanomedicine</MedlineTA>
<NlmUniqueID>101263847</NlmUniqueID>
<ISSNLinking>1176-9114</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488937">M2 protein, Influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">fusion protein</Keyword>
<Keyword MajorTopicYN="N">immunogenicity</Keyword>
<Keyword MajorTopicYN="N">matrix 2 ectodomain</Keyword>
<Keyword MajorTopicYN="N">nodavirus capsid</Keyword>
<Keyword MajorTopicYN="N">subunit vaccine</Keyword>
<Keyword MajorTopicYN="N">virus-like particle</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25897220</ArticleId>
<ArticleId IdType="doi">10.2147/IJN.S77405</ArticleId>
<ArticleId IdType="pii">ijn-10-2751</ArticleId>
<ArticleId IdType="pmc">PMC4396508</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 1999 Oct 9;354(9186):1277-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10520648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 1999 Oct;5(10):1157-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10502819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Jun 20;337(1):149-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15914228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Jan 30;24(5):544-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16169634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2006;3:102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17150104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Jan 31;451(7178):591-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18235503</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Jan 31;451(7178):596-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18235504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Oct 23;27(45):6280-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19840661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chromatogr A. 2010 May 21;1217(21):3473-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20388569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2010 Jun;30(6):439-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20235626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(10):e13162</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20976273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Jan 15;186(2):1022-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21169548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2011 Mar 15;411(2):229-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21237476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2011 Jul;175(1):74-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21536072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Mar 2;30(11):1993-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22226861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Clin Cancer Res. 2012;31:9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22296726</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Sep;12(9):687-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22738893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(9):e45765</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23029232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(3):e59081</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23527091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Apr;98(1):4-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23416215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Feb 15;164(4):1862-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10657635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2000 Aug;182(2):391-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10915067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Dec 1;165(11):6214-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11086055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEMS Immunol Med Microbiol. 2003 Mar 20;35(2):141-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12628550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2004 Feb;85(Pt 2):423-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14769900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):173-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1976 May 7;72:248-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1981 Aug;25(2):315-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6169439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1981 Jul;78(7):4170-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6945577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1985 Mar;40(3):627-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3882238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1993 Jan;74 ( Pt 1):143-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8423445</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1996 Jul;70(7):4411-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8676464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1999 Sep 2;401(6748):76-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10485708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2004 Dec;114(12):1812-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15599406</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000665 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000665 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:25897220 |texte= Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25897220" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |